Oestrogen Therapy Linked to Increased Risk of Benign Breast Disease
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Oestrogen Therapy Linked to Increased Risk of Benign Breast Disease

BETHESDA, Md. -- April 8, 2008 -- Women who took the commonly prescribed conjugated equine oestrogen had more than twice the risk of developing specific types of benign breast disease as women who took a placebo, according to a randomised controlled trial published online April 8 in the Journal of the National Cancer Institute.

The impact of conjugated equine oestrogen on the risk of developing benign proliferative breast disease, a condition that is associated with increased risk of breast cancer, has been unclear. Some studies have reported an association while others have not. In the Women's Health Initiative study, 10,739 postmenopausal women with hysterectomy were assigned to either conjugated equine oestrogen or a placebo. Previous analyses did not show an increase in breast cancer incidence in the women who took oestrogen alone after a median follow-up of 7 years.

To determine whether the hormone increases the risk of benign proliferative breast disease, Tom Rohan, MD, PhD, Chairman, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, and Associate Director, Population Research, Albert Einstein Cancer Center, New York, and colleagues identified and examined noncancerous breast biopsies in each of the Women's Health Initiative trial arms.

A total of 232 cases of benign proliferative breast disease were identified, with 155 cases among the women who took oestrogen supplements and 77 in the placebo group. The risk of developing benign disease increased by more than twofold for women taking conjugated equine oestrogen, compared with those taking a placebo.

"The prevailing hypothesis concerning the natural history of breast cancer is that benign proliferative breast disease without atypia, proliferative disease with atypia, and in situ cancer represent successive steps preceding the development of invasive breast [cancer]. In keeping with this hypothesis, women with benign proliferative breast disease have an increased risk of subsequent breast cancer," the authors write.

Although the women taking conjugated equine oestrogen have not yet shown a significant increased risk of breast cancer in the Women's Health Initiative study, if this hypothesis holds true, they might show increased risk later. Ongoing follow up of the study participants may help to resolve this issue.

SOURCE: Journal of the National Cancer Institute

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities